行情

ALIM

ALIM

Alimera医疗科学
NASDAQ

实时行情|Nasdaq Last Sale

9.44
+0.09
+0.96%
已收盘, 16:00 12/11 EST
开盘
9.66
昨收
9.35
最高
9.90
最低
9.38
成交量
12.56万
成交额
--
52周最高
18.15
52周最低
0.0045
市值
7.03亿
市盈率(TTM)
-3.8609
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALIM 新闻

  • Almira Sciences, Inc 13D filing
  • PR Newswire.11小时前
  • Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019
  • GlobeNewswire.12/04 13:30
  • Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis
  • GlobeNewswire.12/03 13:30
  • Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference
  • GlobeNewswire.11/26 13:30

更多

所属板块

制药
+0.17%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ALIM 简况

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
展开

Webull提供Alimera Sciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。